CD274 and neoplasm: Combined tumoural and stromal PD-L1 expression was associated with higher ORR (p = 0.021) and PFS (p = 0.026) to pembrolizumab, whereas tumour cell staining alone was not (p = 0.088 and 0.096, respectively) [9].